Skip to main content
. 2019 Sep 30;16(10):759–765. doi: 10.30773/pi.2019.06.17

Table 3.

Neuropsychological test scores by group at baseline and 12 weeks

Baseline
12 weeks
p value
Placebo Intervention Placebo Intervention
ADAS-cog 12.48 (3.07) 12.96 (3.50) 11.70 (3.34) 11.20 (3.62) 0.27
CERAD-K total score 66.39 (7.14) 64.56 (8.78) 74.13 (7.03) 71.40 (10.44) 0.59
Verbal Fluency (VF) 13.35 (3.21) 12.80 (3.35) 14.48 (3.13) 13.52 (4.09) 0.63
15-item Boston Naming Test (BNT) 11.57 (1.70) 11.52 (2.45) 12.52 (1.59) 12.52 (1.98) 0.90
Mini Mental Status Examination (MMSE) 26.04 (1.87) 25.80 (2.65) 26.26 (2.60) 25.32 (3.00) 0.26
Word List Memory (WLM) 17.39 (2.62) 16.88 (2.70) 20.65 (3.10) 19.60 (4.45) 0.57
Constructional Praxis (CP) 10.13 (1.22) 9.48 (1.50) 10.26 (1.36) 9.76 (1.42) 0.69
Word List Recall (WLR) 5.30 (0.93) 5.28 (1.60) 6.78 (1.28) 6.60 (1.76) 0.72
Word List Recognition (WLRc) 8.65 (1.50) 8.60 (1.50) 9.43 (0.66) 9.40 (0.87) 0.96
Constructional Recall (CR) 6.48 (2.45) 6.04 (2.56) 8.39 (1.92) 7.88 (2.30) 0.92
Trail making A (seconds) 54.91 (17.33) 63.44 (24.24) 46.52 (17.55) 61.88 (31.05) 0.24
Trail making B (seconds) 186.17 (83.04) 215.13 (86.89) 159.52 (84.79) 194.58 (91.27) 0.77
SMCQ 5.57 (3.75) 6.00 (2.77) 4.83 (3.55) 4.24 (2.40) 0.04

Data are presented as the mean (SD). CERAD-K total score=VF+BNT+WLM+CP+WLR+WLRc. ADAS-cog: Alzheimer’s Disease Assessment Scale-cognitive subscale, CERAD-K: Korean version of the Consortium to Establish a Registry for Alzheimer’s disease